secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2025-02-05T23:59:59+00:00
Accession:  0001140361-25-003082
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

PDS Biotech Reaffirms Guidance to Initiate VERSATILE-003 Phase 3 Trial in Q1 2025
--------------------------------------------------------------------------------

- FDA cleared amended trial design for VERSATILE-003 Phase 3 trial of Versamune HPV plus pembrolizumab in HPV16-positive R/M HNSCC.
- First site initiation expected in Q1 2025; FDA comment window has passed and company on track.
- Fast Track designation from FDA for the combination in recurrent/metastatic HNSCC.
- Companion diagnostic to confirm HPV16-positive status will be used in patient screening.
- Guidance reaffirmed on February 5, 2025 via press release and corporate presentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125003082/0001140361-25-003082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036125003082/ef20042909_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-003082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer